BIG
FATE icon

Brooklyn Investment Group’s Fate Therapeutics FATE Stock Holding History

Brooklyn Investment Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,430
Closed -$8.96K – 2807
2024
Q4 		$8.96K Buy
+5,430
New +$13.7K ﹤0.01% 1019

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Brooklyn Investment Group's FATE Position: Q1 2025 in Review

Brooklyn Investment Group sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 5,430 shares — an estimated $8.96K sold.

Brooklyn Investment Group first reported a position in FATE in Q4 2024 and held it in 1 quarter. The position peaked at $8.96K in Q4 2024. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • Brooklyn Investment Group reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 5,430 Fate Therapeutics shares in Q1 2025, an estimated $8.96K.
  • Brooklyn Investment Group first reported a position in Fate Therapeutics in Q4 2024 and held it in 1 quarter.
  • Brooklyn Investment Group's Fate Therapeutics position peaked at $8.96K in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Brooklyn Investment Group's 13F filing for Q1 2025, filed 13 May 2025.